贝伐珠单抗联合免疫治疗对非鳞非小细胞肺癌血清学指标及预后的影响

Effect of Bevacizumab Combined with Immunotherapy on Serological Indexes and Prognosis of Non-squamous Non-small Cell Lung Cancer

目的探究贝伐珠单抗联合免疫治疗对非鳞非小细胞肺癌(nsNSCLC)血清学指标及预后的影响。方法回顾性分析2018年1月—2020年6月收治94例nsNSCLC的临床资料,根据治疗方案分为对照组和观察组,每组47例。对照组予以纳武利尤单抗治疗,观察组予以贝伐珠单抗联合纳武利尤单抗治疗。探究2组治疗3个周期后临床疗效及血清学指标差异,分析治疗期间不良反应及随访2年生存情况差异。结果观察组治疗3个周期后临床总有效率高于对照组(P<0.05)。治疗3个周期后,2组血清细胞角蛋白19片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)、血管内皮生长因子、转化生长因子-β1、巨噬细胞移动抑制因子水平均较治疗前降低,且观察组低于对照组(P<0.05)。治疗3个周期后,2组血清载脂蛋白A1较治疗前升高,且观察组高于对照组(P<0.05)。2组治疗期间不良反应发生率以及2年生存率比较差异无统计学意义(P>0.05)。结论贝伐珠单抗联合免疫治疗对nsNSCLC的疗效显著,对血清CYFRA21-1、CA125及生长因子有显著调节作用,且不良反应不会显著增加,但对患者生存期影响不显著。

Objective To explore the effect of Bevacizumab combined with immunotherapy on serological indexes and prognosis of non-squamous non-small cell lung cancer(nsNSCLC).Methods Clinical data of 94 patients with nsNSCLC admitted from January 2018 to June 2020 were retrospectively analyzed,and they were divided into control group and observation group according to treatment plan,with 47 cases in each group.The control group was treated with Navulizumab,and the observation group was treated with Bevacizumab combined with Navulizumab.The differences in clinical efficacy and serological indexes between the two groups after 3 cycles of treatment were explored,and the differences in adverse reactions during treatment and survival at 2-year follow-up were analyzed.Results The total effective rate of the observation group was higher than that of the control group after 3 cycles of treatment(P<0.05).After 3 cycles of treatment,the serum levels of cytokeratin 19 fragment antigen 21-1(CYFRA21-1),carbohydrate antigen125(CA125),vascular endothelial growth factor,transforming growth factor-β1 and macrophage migration inhibitor in the two groups were decreased compared with those before treatment,which were lower in the observation group than in the control group(P<0.05).After 3 cycles of treatment,the serum apolipoprotein A1 in the two groups was higher than that before treatment,which was higher in the observation group than in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions and 2-year survival between the two groups(P>0.05).Conclusion Bevacizumab combined with immunotherapy has a significant effect on nsNSCLC,and has a significant regulatory effect on serum CYFRA21-1,CA125 and growth factor,with no significant increase in adverse reactions or significant effect on patient survival.